Mechanisms of Loss of Response to Adalimumab in Crohn's Disease

被引：0
|
作者：
Wolf, Douglas C.
Hauenstein, Scott
Lockton, Steven
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 50 条
  • [41] Infliximab vs Adalimumab for Crohn's Disease
    Dhillon, Angad S.
    Harris, Adam W.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (01) : 210 - 210
  • [42] Adalimumab vasculitis in a patient with Crohn's disease
    Munoz Villafranca, Carmen
    Izu Belloso, Rosa Maria
    Bravo Rodriguez, Maria Teresa
    Basterra Olabarrieta, Susana
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (04): : 296 - 297
  • [43] GAIN for loss: Adalimumab for infliximab-refractory Crohn disease
    Mannon, Peter
    ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) : 888 - 890
  • [44] Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab
    Restellini, Sophie
    Chao, Che-yung
    Lakatos, Peter L.
    Aruljothy, Achuthan
    Aziz, Haya
    Kherad, Omar
    Bitton, Alain
    Wild, Gary
    Afif, Waqqas
    Bessissow, Talat
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (07) : 1531 - 1538
  • [45] Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
    Suzuki, Taketo
    Mizoshita, Tsutomu
    Sugiyama, Tomoya
    Hirata, Yoshikazu
    Kimura, Yoshihide
    Suzuki, Yuka
    Yamada, Tomonori
    Tsukamoto, Hironobu
    Mizushima, Takashi
    Sugimura, Naomi
    Katano, Takahito
    Tanida, Satoshi
    Kataoka, Hiromi
    Sasaki, Makoto
    CASE REPORTS IN GASTROENTEROLOGY, 2019, 13 (01) : 37 - 49
  • [46] Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
    Kaplan, G. G.
    Hur, C.
    Korzenik, J.
    Sands, B. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) : 1509 - 1520
  • [47] Predictors of Loss of Response to Infliximab in Pediatric Crohn's Disease
    Selvakumar, Praveen Kumar Conjeevaram
    Szpunar, Susan
    Lyons, Hernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S594 - S594
  • [48] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
    Colombel, Jean-Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    Enns, Robert
    Hanauer, Stephen B.
    Panaccione, Remo
    Schreiber, Stefan
    Byczkowski, Dan
    Li, Ju
    Kent, Jeffrey D.
    Pollack, Paul F.
    GASTROENTEROLOGY, 2007, 132 (01) : 52 - 65
  • [49] VITAMIN D-RELATED GENETICS AS PREDICTOR OF RESPONSE TO ADALIMUMAB IN CROHN'S DISEASE
    Cusato, J.
    Bertani, L.
    Antonucci, M.
    Tomasello, C.
    Caviglia, G. P.
    Dibitetto, S.
    Massano, A.
    Mangia, M.
    Mula, J.
    Ceccarelli, L.
    Costa, F.
    Zanzi, F.
    Astegiano, M.
    Ribaldone, D. G.
    D'avolio, A.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S127 - S127
  • [50] Rapid response to adalimumab in Crohn's disease patients who have failed infliximah
    D'haens, Geert R.
    Enns, Robert A.
    Van assche, Gen
    Kent, Jeffrey D.
    Li, Ju
    Pollack, Paul F.
    Rubin, David T.
    GASTROENTEROLOGY, 2007, 132 (04) : A502 - A502
12345